Table 1 |
||
|
Clinical characteristics of patients with juvenile rheumatoid arthritis |
||
|
Parameter |
Systemic onset JRA (n = 20) |
Polyarticular JRA (n = 16) or pauciarticular JRA (n = 4) |
|
|
||
|
Male/female |
9/11 |
14/6 |
|
Mean age, years (range) |
11.5 (2–23) |
12.8 (3–22) |
|
Mean disease duration, years (range) |
4.1 (0.2–16) |
5.8 (0.9–15) |
|
No. with active arthritis (%) |
17 (85) |
17 (85) |
|
No. with active systemic disease (%) |
8 (40) |
- |
|
Mean ESR, mm/h (range) |
30 (5–85) |
21 (5–57) |
|
No. (%) receiving |
||
|
Prednisone |
6 (30) |
3 (15) |
|
Methotrexate |
12 (60) |
10 (50) |
|
TNF-blocking agent |
3 (15) |
5 (25) |
|
Intra-articular steroids |
1 (5) |
4 (20) |
|
NSAID |
17 (85) |
18 (90) |
|
|
||
|
ESR, erythrocyte sedimentation rate; JRA, juvenile rheumatoid arthritis; NSAID, non-steroidal anti-inflammatory drugs; TNF, tumor necrosis factor. |
||
|
Villanueva et al. Arthritis Res Ther 2005 7:R30 doi:10.1186/ar1453 |
||
